Recent

% | $
Quotes you view appear here for quick access.

pSivida Corp. Message Board

godwintom 19 posts  |  Last Activity: 6 hours ago Member since: Dec 26, 2014
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    What's the story with our SP???

    by aussiefrank55 11 hours ago
    godwintom@att.net godwintom 6 hours ago Flag

    J.D., I'm sorry but will you explain to all us dummies how would they be able to do that? If there is so much TRUE BLUE sky the s.p. would definitely be going up. The problem is that the sky is cloudy for PSDV at this point. Investors want to see a clear path toward earnings, right now they don't see that. You might want to reconsider your posts because they are not reflecting anything but a lot of hope. We've had an over abundance of hope for years with PSDV and it's running pretty darned thin. I'm sick of hope, I want action from this company and no more dilution.

  • Reply to

    Any news on the FDA meeting?

    by antisense_science Mar 18, 2015 8:08 AM
    godwintom@att.net godwintom Mar 20, 2015 8:15 PM Flag

    J.D., I'm not ruling out Roche in fact it was at the top of my list at one point. However, at this point I'm not certain how many companies have actually done product eval's with PSDV but what worries me more is how many have and things didn't work out. As Mick points out the clock is ticking. Time is not on PSDV's side with limited funds, uncertain cash flow from Iluvien and fierce competition. I don't want to see further stock dilution to finance additional stock shares for management until they perform for stockholders, especially when we really don't have a true handle on Uveitis income possibilities. There will be upcoming catalysts but will they be strong enough to move the needle or just another bleep on the radar. More pressure needs to be applied to management to produce more than what is presently being done. Quick story= approx. 5yrs. ago the s.p. was 4.00 plus after reverse split, today we are at about the same range. What happened? Hold & Hope till midyear.

    Sentiment: Hold

  • Reply to

    Any news on the FDA meeting?

    by antisense_science Mar 18, 2015 8:08 AM
    godwintom@att.net godwintom Mar 19, 2015 11:25 AM Flag

    Mick, As you said earlier all the true longs feel like redheaded stepchildren with milk bottle glasses. J.D., should understand that Genentech and PSDV are two totally different entities, many firms are presently working on sustained delivery devices that's why PSDV needs to deliver soon or they will be left in the aftermath.. No large partners and no home runs. As you so correctly state-----and we wait, but not patiently anymore.

    Sentiment: Hold

  • Reply to

    Any news on the FDA meeting?

    by antisense_science Mar 18, 2015 8:08 AM
    godwintom@att.net godwintom Mar 18, 2015 7:54 PM Flag

    J.D., The catalyst remained delayed because they were and are still what is called (forward looking statements) and apparently premature statements. If they had been in the present tense they would have materialized by now. There is a big difference. I believe that they do have some good technology but they are buying time in the hope that they will be able to carry it out into something tangible. Have you thought about how many so called catalyst mentioned by the co., seems to have faded away with no more mention? How do you feel about that? When companies have the freedom to not update future developments they could be used as bait. I believe there should be more visibility in all publicly traded companies and there are some that follow this practice to the letter. I, at one time was also extremely excited about PSDV"s future but after many, many delays, become more skeptical as does the market. If this was not the case this stock would be trading at 15-20 dollars base on the purported information. I sold 13% of my holdings as a hedge against this continual practice of kicking the can down the proverbial road of forward looking statements. It's time for the management to produce. Iluvien has been going on for 10 years. What else has been developed to a point of producing money? 10 years. of talk and can kicking. I will continue to hold my stock until mid year in hopes something will happen for the good.

    Sentiment: Hold

  • Reply to

    Any news on the FDA meeting?

    by antisense_science Mar 18, 2015 8:08 AM
    godwintom@att.net godwintom Mar 18, 2015 3:59 PM Flag

    If there were any news and it turns out to be negative, we the lowly common stockholders will be the very last to know. Sorry for the negativity but time is running out for this company. Hello,----------- as the old song goes, It's soon or never.

  • Reply to

    alim qtrly report looks like @#$%

    by gswkool Mar 5, 2015 12:45 PM
    godwintom@att.net godwintom Mar 5, 2015 3:38 PM Flag

    Anti, I pretty much agree with most of what you have stated. I firmly believe that there are other indications that will be developed that will outperform Iluvien in the area of injection frequencies thus more office calls to take care of the Doc, no argument there. I also believe that patients, not going blind, is more relevant than generating profit and office calls. There is a building consensus that all other available therapies are failing in about 40-50% of the patients with DME and many are suffering in the early stages. Now, I would say that most Doc's don't want to face malpractice charges for not administering the needed therapy. I mean who would let a patient go blind to make a few more bucks.

    Sentiment: Buy

  • Reply to

    alim qtrly report looks like @#$%

    by gswkool Mar 5, 2015 12:45 PM
    godwintom@att.net godwintom Mar 5, 2015 1:49 PM Flag

    What did you expect? The Brits are basically the only contributor, at this point.. Germany sucks and are trying to game their efforts, but that will change. The same with France only worse. Watch them change their other mind, after the launch in the U.S. seasons a little bit.

    Sentiment: Buy

  • Reply to

    I got cold feet prior to alim qtr release

    by monte6811 Mar 4, 2015 6:20 PM
    godwintom@att.net godwintom Mar 4, 2015 9:03 PM Flag

    Monte, We all have our own trigger points for making a move and I respect yours. In my estimation Alimera's qtrly sales should not have been a qualifier for buying or selling, in and by itself. If there had been adverse publicity preceding the release, it could have signaled such a move. If the analyst covering this stock had been up on their game, they would have forecast lower sales due to the extreme difficulty in dealing with Germany and France not to mention the laid back nature of the E.U. in general. I also believe the E.U. is taking a wait and see attitude concerning the U.S. launch, in which we are talking a much, much different environment. The relaxed labeling of Iluvien is one of the key differences in this product. The FDA is essentially saying, our eyes have been opened and we can now see that you have a better product. That's a huge roadblock that is now gone, after all, we all have experienced the ride concerning the FDA and this product.

    Sentiment: Buy

  • godwintom@att.net by godwintom Feb 28, 2015 2:02 PM Flag

    Add Brazil to the mix, it's in the works for transformation of the whole hemisphere CZZ.

  • godwintom@att.net godwintom Feb 19, 2015 8:33 PM Flag

    J.D., It's not the same indication, Iluvien has a different labeling but that will probably change to the advantage of Iluvien. As the other products are failing as the disease progresses.

  • Reply to

    Europe

    by ruraddy Feb 9, 2015 10:41 AM
    godwintom@att.net godwintom Feb 9, 2015 12:14 PM Flag

    It's all about money, of which Alimera needs to stretch their limited supply and concentrate on the most productive areas first. As you know the E.U. has been a slow process but will probably pickup as the U.S. gets Iluvien going here. Makes sense to me. Europe is not nearly as progressive in some areas, just their laid back style.

    Sentiment: Buy

  • godwintom@att.net godwintom Feb 8, 2015 2:55 PM Flag

    Terry, Truly great and informative article.This type of p.r. can't do anything but enhance the drug delivery concept, thanks.

  • godwintom@att.net godwintom Feb 6, 2015 2:23 PM Flag

    Mick, It would be terrible not not stick now. I'm like most other folks, just wanting to push for more visibility. I am happy for now with what Paul provided. I think the stock is back to a buy. I continue to hold all my shares, unfortunately I don't have any spare cash for additional purchases. Maybe Terry would make me a loan, ha-ha-ha.

    Sentiment: Buy

  • godwintom@att.net godwintom Feb 6, 2015 10:56 AM Flag

    Terry, have you noticed the description for PSDV/Industry has been changed to drugs--generic? it's on Yahoo description and information/profile. Sounds like there could be a tie in here with PFE. I don't know and really don't care but i am very happy with Paul's recent comments.

    Sentiment: Buy

  • Reply to

    Meniscus regenerated with 3-D printed implant

    by terry290737 Feb 5, 2015 11:01 AM
    godwintom@att.net godwintom Feb 5, 2015 5:42 PM Flag

    Terry, I missed your previous article pertaining to this subject but will read it asap. As you probably know this very subject was discussed by Paul on today's presentation and he was very clearly excited about it and all it's possible indications for many areas of the body. Thanks for getting back. Appreciate your time and help in keeping us better informed.

    Sentiment: Hold

  • Reply to

    Meniscus regenerated with 3-D printed implant

    by terry290737 Feb 5, 2015 11:01 AM
    godwintom@att.net godwintom Feb 5, 2015 12:53 PM Flag

    Terry, Informative article, appreciate you sharing, goes to show the many and varied treatments that are becoming available for different ailments. I understand that PSDV has interest in this area.. This indication is apparently to restore the shielding area to original condition and helps prevent arthritis from getting a foothold and PSDV is primarily going for pain control of the jointed area with the possibility of cure. At least that's my simplistic take on it.

    Sentiment: Hold

  • godwintom@att.net by godwintom Feb 4, 2015 3:44 PM Flag

    Only have one point of view, their own, they disrespect other views unless it lines up with theirs. They also get low down and dirty through name calling. Why don't you guys (man up)? you know who you are, so why not apologize? Do it now! or at least stop this nonsense of belittling other people.

  • godwintom@att.net by godwintom Feb 3, 2015 11:20 PM Flag

    So if PSDV has anything of credibility they will be referencing it at this meeting coming up on the 9th. of Feb.
    I would think that most of us whom have been around for awhile should be able to read between the lines on it's worth. It sure would be nice to see some gain commensurate with the pain most of us have experienced. Time has become our enemy as the field is progressing and we seem to be regressing. Let the true science and ability come out whatever it may be one way or the other.

    The market seems to be reflecting some doubt regarding ALIM/PSDV near term ability to produce healthy sales in the E.U.. and as we can all see the market is not impressed with the upcoming launch of Iluvien in the U.S. were it so we would be seeing that through increasing s.p.. Hopefully this will change as the time grows closer but the way it's looking there will be very few gimmee's. JMO

    Sentiment: Hold

  • Reply to

    Information please

    by stockaroo87 Jan 24, 2015 11:46 PM
    godwintom@att.net godwintom Jan 25, 2015 5:18 PM Flag

    I'm trying to determine their average per barrel cost?

PSDV
3.85-0.10(-2.53%)Apr 1 4:00 PMEDT